We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
If You Invested $1000 in Boston Scientific a Decade Ago, This is How Much It'd Be Worth Now
Read MoreHide Full Article
For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and industries.
Another thing that can drive investing is the fear of missing out, or FOMO. This particularly applies to tech giants and popular consumer-facing stocks.
What if you'd invested in Boston Scientific (BSX - Free Report) ten years ago? It may not have been easy to hold on to BSX for all that time, but if you did, how much would your investment be worth today?
Boston Scientific's Business In-Depth
With that in mind, let's take a look at Boston Scientific's main business drivers.
Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success.
Boston Scientific reorganized its operational structure and aggregated its core businesses, each of which generates revenues from the sale of Medical Devices, into two reportable segments, MedSurg (35.8% of total revenue; 2024 organic growth was 7.5% over 2023) and Cardiovascular (accounting for the rest; 21.9% organic growth in 2024).
The Cardiovascular segment coprises Cardiology division (represents the combined former Rhythm Management and Interventional Cardiology businesses) and Peripheral Interventions.
MedSurg group comprises 3 sub segments, viz. Endoscopy; Urology; and Neuromodulation.
The company is one of the leading players in the interventional cardiology market with its coronary stent product offerings. Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. In addition, in Europe, it markets the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System featuring an ultra-thin abluminal (outer) bioabsorbable polymer coating.
The company also markets balloon catheters, rotational atherectomy systems, guide wires, guide catheters, embolic protection devices, and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures, as well as intravascular ultrasound (IVUS) imaging systems.
Bottom Line
Anyone can invest, but building a successful investment portfolio requires research, patience, and a little bit of risk. So, if you had invested in Boston Scientific, ten years ago, you're likely feeling pretty good about your investment today.
A $1000 investment made in November 2015 would be worth $5,367.55, or a 436.76% gain, as of November 11, 2025, according to our calculations. Investors should note that this return excludes dividends but includes price increases.
In comparison, the S&P 500's gained 228.21% and the price of gold went up 264.42% over the same time frame.
Looking ahead, analysts are expecting more upside for BSX.
Despite macroeconomic issues, primarily tariff tensions and related cost inflation, Boston Scientific is seeing strength across its target markets. Strong demand for its MedSurg and Cardiovascular lines, traction in the United States and internationally, supported by launches of next-generation devices such as the WATCHMAN FLX Pro (approved in China) and the FARAPULSE PFA System, are important drivers. Contributions from accretive acquisitions (newer being Elutia) further complement the growth trajectory. The Pain and Brain franchises are gaining solid traction in 2025 supported by momentum in Intracept and the Cartesia X/HX leads. The 2025 organic growth guidance of 15.5 % builds confidence in the stock. On the flip side, mounting costs remain a concern. Tariffs continue to impact margins and FX exposure remains a structural risk.
The stock has jumped 6.28% over the past four weeks. Additionally, no earnings estimate has gone lower in the past two months, compared to 10 higher, for fiscal 2025; the consensus estimate has moved up as well.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
If You Invested $1000 in Boston Scientific a Decade Ago, This is How Much It'd Be Worth Now
For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and industries.
Another thing that can drive investing is the fear of missing out, or FOMO. This particularly applies to tech giants and popular consumer-facing stocks.
What if you'd invested in Boston Scientific (BSX - Free Report) ten years ago? It may not have been easy to hold on to BSX for all that time, but if you did, how much would your investment be worth today?
Boston Scientific's Business In-Depth
With that in mind, let's take a look at Boston Scientific's main business drivers.
Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success.
Boston Scientific reorganized its operational structure and aggregated its core businesses, each of which generates revenues from the sale of Medical Devices, into two reportable segments, MedSurg (35.8% of total revenue; 2024 organic growth was 7.5% over 2023) and Cardiovascular (accounting for the rest; 21.9% organic growth in 2024).
The Cardiovascular segment coprises Cardiology division (represents the combined former Rhythm Management and Interventional Cardiology businesses) and Peripheral Interventions.
MedSurg group comprises 3 sub segments, viz. Endoscopy; Urology; and Neuromodulation.
The company is one of the leading players in the interventional cardiology market with its coronary stent product offerings. Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. In addition, in Europe, it markets the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System featuring an ultra-thin abluminal (outer) bioabsorbable polymer coating.
The company also markets balloon catheters, rotational atherectomy systems, guide wires, guide catheters, embolic protection devices, and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures, as well as intravascular ultrasound (IVUS) imaging systems.
Bottom Line
Anyone can invest, but building a successful investment portfolio requires research, patience, and a little bit of risk. So, if you had invested in Boston Scientific, ten years ago, you're likely feeling pretty good about your investment today.
A $1000 investment made in November 2015 would be worth $5,367.55, or a 436.76% gain, as of November 11, 2025, according to our calculations. Investors should note that this return excludes dividends but includes price increases.
In comparison, the S&P 500's gained 228.21% and the price of gold went up 264.42% over the same time frame.
Looking ahead, analysts are expecting more upside for BSX.
Despite macroeconomic issues, primarily tariff tensions and related cost inflation, Boston Scientific is seeing strength across its target markets. Strong demand for its MedSurg and Cardiovascular lines, traction in the United States and internationally, supported by launches of next-generation devices such as the WATCHMAN FLX Pro (approved in China) and the FARAPULSE PFA System, are important drivers. Contributions from accretive acquisitions (newer being Elutia) further complement the growth trajectory. The Pain and Brain franchises are gaining solid traction in 2025 supported by momentum in Intracept and the Cartesia X/HX leads. The 2025 organic growth guidance of 15.5 % builds confidence in the stock. On the flip side, mounting costs remain a concern. Tariffs continue to impact margins and FX exposure remains a structural risk.
The stock has jumped 6.28% over the past four weeks. Additionally, no earnings estimate has gone lower in the past two months, compared to 10 higher, for fiscal 2025; the consensus estimate has moved up as well.